Oruka Therapeutics (NASDAQ:ORKA) Trading Down 5% - Time to Sell?

Key Points

• Oruka Therapeutics shares fell 5% to approximately $86.60, with trading volume down 96% from the average. The company has a $6.03 billion market capitalization and trades below its 50-day moving average of $94.60.
• Analyst sentiment remains broadly positive, with 10 Buy ratings and one Sell rating producing a “Moderate Buy” consensus and an average price target of $134.30. However, Wall Street Zen recently downgraded the stock to Sell.
• The clinical-stage biopharmaceutical company missed its latest quarterly EPS estimate, reporting a loss of $0.55 versus the expected $0.51 loss. Insiders sold 83,116 shares worth $6.6 million in the last quarter, while Oruka’s lead candidate, ONCT-01, remains in Phase 1 trials for advanced solid tumors.

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) were down 5% during trading on Monday . The company traded as low as $87.57 and last traded at $86.5970. Approximately 43,076 shares changed hands during trading, a decline of 96% from the average daily volume of 1,112,356 shares. The stock had previously closed at $91.14.

Analysts Set New Price Targets

Several equities research analysts have recently commented on ORKA shares. Wall Street Zen lowered Oruka Therapeutics from a "hold" rating to a "sell" rating in a research note on Sunday, August 16th. UBS Group raised their price objective on Oruka Therapeutics from $100.00 to $130.00 and gave the company a "buy" rating in a research note on Wednesday, July 1st. BTIG Research reaffirmed a "buy" rating and set a $151.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Piper Sandler reiterated an "overweight" rating and set a $180.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. Finally, Weiss Ratings raised Oruka Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Wednesday, July 15th. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Oruka Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $134.30.

Oruka Therapeutics Stock Down 0.1%

The business's fifty day moving average price is $94.60 and its 200 day moving average price is $67.75. The firm has a market capitalization of $6.03 billion, a PE ratio of -44.85 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). As a group, sell-side analysts forecast that Oruka Therapeutics, Inc. will post -2.33 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Joana Goncalves sold 7,947 shares of the company's stock in a transaction on Monday, June 15th. The stock was sold at an average price of $69.28, for a total value of $550,568.16. Following the completion of the transaction, the insider directly owned 32,718 shares in the company, valued at approximately $2,266,703.04. This represents a 19.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Carl Dambkowski sold 22,417 shares of the stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $70.13, for a total value of $1,572,104.21. Following the transaction, the director owned 51,326 shares in the company, valued at $3,599,492.38. This trade represents a 30.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 83,116 shares of company stock worth $6,636,533. 23.49% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Algert Global LLC grew its position in Oruka Therapeutics by 3.5% during the second quarter. Algert Global LLC now owns 5,380 shares of the company's stock valued at $512,000 after acquiring an additional 180 shares during the period. Nykredit A S purchased a new position in shares of Oruka Therapeutics in the 2nd quarter worth about $29,000. Royal Bank of Canada lifted its stake in shares of Oruka Therapeutics by 47.2% in the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company's stock valued at $34,000 after purchasing an additional 365 shares in the last quarter. Kennedy Capital Management LLC grew its holdings in shares of Oruka Therapeutics by 0.9% during the 4th quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company's stock worth $1,476,000 after purchasing an additional 420 shares during the period. Finally, AlphaCentric Advisors LLC grew its holdings in shares of Oruka Therapeutics by 5.8% during the 1st quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company's stock worth $564,000 after purchasing an additional 626 shares during the period. Institutional investors and hedge funds own 56.44% of the company's stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source